Welcome to our dedicated page for Northwest Bio SEC filings (Ticker: NWBO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Northwest Biotherapeutics, Inc. (NWBO) SEC filings page on Stock Titan provides centralized access to the company’s regulatory disclosures as a reporting issuer whose common stock trades on the OTCQB. Through these filings, investors can review how Northwest Biotherapeutics describes its business of developing DCVax dendritic cell-based immunotherapies for solid tumor cancers, along with details on governance, financing, and capital structure.
Key documents include annual reports on Form 10-K and quarterly reports on Form 10-Q, where the company discusses its DCVax-L and DCVax-Direct programs, clinical trial status, manufacturing initiatives such as the Flaskworks system and the Sawston, UK facility, and risk factors relevant to its operations. These reports also provide information on research collaborations, in-licensed dendritic cell technology portfolios, and the acquisition of Advent BioServices Ltd.
Frequent current reports on Form 8-K highlight material events such as convertible note financings, commercial loan agreements, filing of shelf registration statements on Form S-3, settlement of litigation related to option awards, and the closing of the Advent acquisition. 8-K filings also document shareholder meeting outcomes, including votes on director elections, auditor ratification, increases in authorized common stock, and advisory votes on executive compensation.
Proxy statements on Schedule 14A (DEF 14A) provide further detail on corporate governance, board composition, compensation policies, and proposals presented to stockholders at annual meetings. Amendments to the certificate of incorporation, such as increases in authorized shares of common stock, are described in both proxy materials and related 8-K filings.
On Stock Titan, these filings are updated as they are released through EDGAR. AI-powered summaries help explain lengthy documents by highlighting core business descriptions, key financing terms, changes in share authorization, and other items that may affect NWBO’s capital structure and strategic flexibility. Users can also review filings related to registration statements and other corporate actions to build a more complete picture of Northwest Biotherapeutics’ regulatory and financial history.
Northwest Biotherapeutics notified the SEC it cannot timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2025. The company cites complex accounting issues from its acquisition of Advent BioServices, including differences between UK GAAP and US GAAP, and says it will file the 2025 Annual Report as soon as reasonably practicable.
Northwest Biotherapeutics, Inc. has agreed to settle a Delaware Court of Chancery lawsuit over option awards granted to management and directors in 2020. Under the Settlement Agreement, the company’s insurance carriers will pay $2.25 million to the company and 17% of the challenged 2020 stock options will be cancelled, resolving all claims between the parties.
The lead plaintiff intends to ask the court for up to $3,500,000 in attorneys’ fees and expenses, which would be paid separately by the company’s insurers. The agreement and any fee award must be approved at a hearing scheduled for March 16, 2026 at the Leonard L. Williams Justice Center in Wilmington, Delaware.
Northwest Biotherapeutics, Inc. reported the results of its annual stockholder meeting held on December 29, 2025. A quorum was reached, with 1,192,487,345 shares representing 77.4% of the total combined voting power present in person or by proxy.
Stockholders, voting common and preferred shares as a single class, elected Pat Sarma to a new three-year term as a Class II director and ratified Cherry Bekaert LLP as independent registered public accounting firm for the fiscal year ending December 31, 2025.
They also approved an amendment to the Certificate of Incorporation to increase authorized common stock from 1,700,000,000 to 2,600,000,000 shares, and gave advisory approval to the Company’s executive compensation. On December 30, 2025, the Company filed the Certificate of Amendment in Delaware to effect the authorized share increase.
Northwest Biotherapeutics, Inc. is asking stockholders to vote at its December 29, 2025 annual meeting on several key items. Stockholders will elect one Class II director, Pat Sarma, to a three-year term and vote on ratifying Cherry Bekaert LLP as independent auditor for 2025.
A major proposal seeks approval to amend the Certificate of Incorporation to increase authorized common shares from 1.7 billion to 2.6 billion. The company states this is intended to support future capital raising, satisfy existing options, warrants and convertible securities, and potentially provide equity incentives. As of November 14, 2025, there were 1,528,682,082 common shares and 818,142 preferred shares outstanding.
Stockholders will also cast an advisory "say-on-pay" vote on 2024 executive compensation, including total 2024 pay of $1.225 million for CEO Linda Powers and $975,000 for former General Counsel Leslie Goldman. The proxy describes board structure, committee responsibilities, related-party arrangements such as the Advent BioServices contracts ahead of its acquisition, and detailed voting procedures for both record and beneficial holders.
Northwest Biotherapeutics, Inc. is registering 21,739,130 shares of common stock at an offering price of $0.23 per share in connection with a $5,000,000 convertible promissory note financing with YA II PN, Ltd. The company expects net proceeds of approximately $4,750,000 after an original issue discount and expenses. These shares are reserved to repay principal and any accrued amounts on the 12‑month, zero‑interest Note, which carries a 5% original issue discount and is convertible, at the holder’s option, at a small discount to the then‑prevailing market price, subject to monthly conversion limits.
Following this offering, the company estimates it will have 1,562,421,212 shares of common stock outstanding. Net proceeds are earmarked for general corporate purposes, including working capital, capital expenditures such as UK production facilities, research and development, regulatory affairs, clinical trials, and potential technology acquisitions and investments.
Northwest Biotherapeutics, Inc. entered into a $5 million convertible promissory note financing with YA II PN, Ltd. The company plans to use the cash for construction and equipment for its first Grade C manufacturing suite at its Sawston, UK facility, and for ongoing operations. The note has a 12-month term with no payments due until maturity, carries a 5% original issue discount, and does not bear interest.
During the term, the note is convertible at the holder’s option at a small discount to the then prevailing market price. Conversion amounts are generally limited to about one fifth of the $5 million note in any calendar month, unless the conversion price is above $0.29. The agreement includes customary default provisions.
Northwest Biotherapeutics (NWBO) filed its Q3 2025 10‑Q reporting continued losses and tight liquidity. The company posted a net loss of $26.8 million for the quarter and $61.6 million year‑to‑date, on research and other revenue of $200,000 for the quarter. Operating expenses were $14.5 million in Q3, split between R&D $7.5 million and G&A $7.1 million.
Cash and equivalents were $4.56 million at September 30, 2025, after $30.0 million net cash used in operations year‑to‑date. Total liabilities were $125.9 million and stockholders’ deficit was $(108.6) million. The company disclosed substantial doubt about its ability to continue as a going concern. Financing activities included issuing common stock for $17.3 million net cash and converting debt and interest into 107.0 million shares ($27.6 million non‑cash). Convertible notes measured at fair value rose to $50.6 million, and interest expense was $2.6 million in Q3. NWBO agreed to acquire Advent BioServices on August 27, 2025 and closed the deal on October 24, 2025. Shares outstanding were 1,540,682,082 as of November 13, 2025.
Northwest Biotherapeutics (NWBO) entered into a $5,505,000 commercial loan with Streeterville Capital, LLC. The loan has a 22‑month term, bears 8% annual interest, and includes a 10% original issue discount. There are no repayments for the first eight months, with repayments beginning on June 26, 2026.
After repayments begin, the note amortizes over 14 equal monthly installments of principal at 110% of the pro rata amount, plus accrued interest. The company may prepay at its election, subject to a 10% prepayment charge, and the agreement contains customary default and acceleration provisions. Proceeds will support ongoing business operations.
Northwest Biotherapeutics (NWBO) closed its acquisition of Advent BioServices, which is now a wholly owned subsidiary. The deal transfers Advent’s fixed assets, including extensive cryostorage and related equipment, plus intellectual property and other intangibles, to NWBO.
No new shares are being issued. Instead, 19 million previously issued NWBO securities are reverting to the company, comprising 13.5 million shares and 5.5 million options. Cash consideration consists of a payment of £1.4 million and the net amount of accounts payable due to Advent for prior services. Payments will be made in installments over two years, with potential acceleration after regulatory approval of DCVax-L. Installments begin 90 days after the October closing, and the net accounts payable is determined as of the closing date.